Cargando…

Healthcare Resource Utilization in Patients Receiving Omalizumab for Allergic Asthma in a Real-World Setting

INTRODUCTION: Inadequately controlled asthma is associated with increased healthcare resource utilization. The eXpeRience registry was initiated to evaluate real-world outcomes in patients receiving omalizumab for uncontrolled persistent allergic asthma. The current analysis of data from the eXpeRie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Braunstahl, Gert-Jan, Canvin, Janice, Peachey, Guy, Chen, Chien-Wei, Georgiou, Panayiotis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4254868/ https://www.ncbi.nlm.nih.gov/pubmed/25371373 http://dx.doi.org/10.1007/s13554-014-0019-z

Ejemplares similares

Healthcare utilization and indirect cost of treatment associated with severe allergic asthma in a real-world setting
por: Braunstahl, Gert-Jan, et al.
Publicado: (2013)

Reduction in oral corticosteroid use in patients receiving omalizumab for allergic asthma in the real-world setting
por: Braunstahl, Gert-Jan, et al.
Publicado: (2013)

Reduction in oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma receiving omalizumab in a real-world setting
por: Braunstahl, Gert-Jan, et al.
Publicado: (2013)

4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
por: Snelder, S. M., et al.
Publicado: (2017)

Omalizumab in the treatment of severe allergic (IgE-mediated) asthma: an update on recent developments
por: Humbert, Marc, et al.
Publicado: (2013)

Real-World Observational Study on the Characteristics and Treatment Patterns of Allergic Asthma Patients Receiving Omalizumab in Canada
por: Lee, Jason K, et al.
Publicado: (2020)

Omalizumab for Severe Asthma: Beyond Allergic Asthma
por: Loureiro, C. C., et al.
Publicado: (2018)

Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia
por: Torres-Duque, Carlos A., et al.
Publicado: (2022)

Effectiveness of Omalizumab in Severe Allergic Asthma: A Retrospective UK Real-World Study
por: Barnes, Neil, et al.
Publicado: (2013)

Omalizumab: the evidence for its place in the treatment of allergic asthma
por: McNicholl, Diarmuid M., et al.
Publicado: (2008)

Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma
por: Kotoulas, Serafeim Chrysovalantis, et al.
Publicado: (2022)

Omalizumab and IgE in the Control of Severe Allergic Asthma
por: Gon, Yasuhiro, et al.
Publicado: (2022)

Omalizumab in the management of patients with allergic (IgE-mediated) asthma
por: Sandström, Thomas
Publicado: (2009)

270 Clinical Experience in Allergic Asthma Patients: Omalizumab with Immunotherapy
por: Yalcin, Arzu Didem, et al.
Publicado: (2012)

Omalizumab for severe allergic asthma: a life changing drug?
por: Mesonjesi, Eris, et al.
Publicado: (2015)

Omalizumab as add-on therapy in patients with asthma and allergic bronchopulmonary aspergillosis
por: da Cunha, Fernanda Sales, et al.
Publicado: (2018)

Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin
por: Metz, Martin, et al.
Publicado: (2017)

Real-world effectiveness and safety of omalizumab in patients with uncontrolled severe allergic asthma from the Czech Republic
por: Kirchnerová, Olga Růžičková, et al.
Publicado: (2018)

Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic on H(1) Antihistamines: A Randomized, Placebo-Controlled Study
por: Saini, Sarbjit S, et al.
Publicado: (2015)

Omalizumab in Children with Severe Allergic Asthma: The Italian Real-Life Experience
por: Licari, Amelia, et al.
Publicado: (2017)

Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US
por: Zafari, Zafar, et al.
Publicado: (2018)

Omalizumab and unmet needs in severe asthma and allergic comorbidities in Japanese children
por: Nishima, Sankei, et al.
Publicado: (2019)

Omalizumab for the treatment of severe allergic asthma in children: A tale of two
por: Brannick, Sinéad, et al.
Publicado: (2022)

Specific IgE Response and Omalizumab Responsiveness in Severe Allergic Asthma
por: Tajiri, Tomoko, et al.
Publicado: (2023)

Selectivity and Specificity Are the Keys to Cost-Effective Use of Omalizumab for Allergic Asthma
por: Curtiss, Frederic R.
Publicado: (2005)

The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study
por: Bhutani, Mohit, et al.
Publicado: (2017)

155 Omalizumab Improves Asthma but not Nasal Symptoms in Japanese Patients With Severe Allergic Asthma and Rhinitis
por: Nishihara, Fuyumi, et al.
Publicado: (2012)

Sex, Allergic Diseases and Omalizumab
por: Sirufo, Maria Maddalena, et al.
Publicado: (2022)

Long-term benefits of omalizumab in a patient with severe non-allergic asthma
por: Menzella, Francesco, et al.
Publicado: (2011)

In search of clinically relevant parameters to monitor successful omalizumab therapy in allergic asthma
por: Probst, M., et al.
Publicado: (2019)

Omalizumab in middle-aged or older patients with severe allergic asthma-COPD overlap
por: Ricciardi, Luisa, et al.
Publicado: (2022)

Influence of Genetics on the Response to Omalizumab in Patients with Severe Uncontrolled Asthma with an Allergic Phenotype
por: Rojo-Tolosa, Susana, et al.
Publicado: (2023)

Real-life Effectiveness of Omalizumab in Patients with Severe Allergic Asthma: RELIEF Study
por: Al Ahmad, Mona, et al.
Publicado: (2022)

Real-World Safety and Effectiveness of Omalizumab in Moderate to Severe Allergic Asthma Patients in China: A Post-Authorization Study
por: Su, Nan, et al.
Publicado: (2023)

Omalizumab for Chinese patients with moderate-to-severe allergic asthma in real-world clinical setting: a prospective, observational study
por: Wang, Wen, et al.
Publicado: (2023)

Omalizumab Effectiveness in Severe Allergic Asthma with Multiple Allergic Comorbidities: A Post-Hoc Analysis of the STELLAIR Study
por: Just, Jocelyne, et al.
Publicado: (2021)

Poster 1012: Safety and efficacy of omalizumab in 10 children with asthma and other allergic comorbidities
por: Aguiar, Rita, et al.
Publicado: (2014)

Cost-Effectiveness of Bronchial Thermoplasty, Omalizumab, and Standard Therapy for Moderate-to-Severe Allergic Asthma
por: Zafari, Zafar, et al.
Publicado: (2016)

Description of Baseline Characteristics of Pediatric Allergic Asthma Patients Including those Initiated on Omalizumab
por: Kavati, Abhishek, et al.
Publicado: (2018)

Effectiveness of benralizumab for allergic and eosinophilic predominant asthma following negative initial results with omalizumab
por: Minami, Daisuke, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_lseccqqilns5g404s1aonilq9i